Skip to content

A clinical trial to study the effect of intra-operative use of platelet rich plasma on the outcome of Hair restoration surgery

Randomized Control Trial to study the efficacy & safety of intraoperative Platelet rich plasma in hair restoration surgery by increasing hair density of implanted scalp vs hair density achieved with hair restoration alone. A pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012585
Enrollment
20
Registered
2018-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Androgenetic Alopecia

Interventions

Intervention1: platelet rich plasma : All Patients undergoing hair restoration surgery with intra-operative use of platelet rich plasma Control Intervention1: without platelet rich plasma : All Pat

Sponsors

Office of the Director General Armed Forces Medical Services New Delhi India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All male patients presenting with Grade IV-VI of Hamilton & Norwood classification for Androgenetic Alopecia and on treatment with topical minoxidil and/or oral Finasteride/ Deutasteride for a period not less than six months would be included in the study.

Exclusion criteria

Exclusion criteria: Individuals less than 25 yrs of age, degree of baldness <Grade IV of Hamilton & Norwood classification for Androgenetic Alopecia, those with any co-morbidities, previous hair restoration surgery, receiving Platelet rich plasma therapy, having a tendency to form keloids or hypertrophic scars, poor density of donor area( <40 follicular units/cm2), alopecia other than AGA and those with scalp disease would be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Efficacy outcome would be determined by measuring the number of follicular units in the outlined areas using a folliculoscope to determine the density for subjects and controls.Timepoint: monthly review for 07 months

Secondary

MeasureTime frame
The safety outcome would be assessed by looking for any evidence of infection, sterile folliculitis, cysts or scarring.Timepoint: Weekly for 4 weeks

Countries

India

Contacts

Public ContactLt Col Vikas Pathania

Command Hospital

vikascongo@yahoo.co.in9599847519

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026